Praxis Precision Medicines, Inc. (PRAX)
| Previous Close | 55.16 |
| Open | 55.56 |
| Bid | 54.29 x 200 |
| Ask | 54.90 x 100 |
| Day's Range | 54.49 - 55.56 |
| 52 Week Range | 12.45 - 67.21 |
| Volume | |
| Avg. Volume | 209,088 |
| Market Cap | 936.994M |
| Beta (5Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.69 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 135.00 |
ZacksWall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswirePraxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showca
ZacksPraxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
